Melbourne, Australia; 24 February 2022: Starpharma Holdings Limited The Board of Starpharma (ASX: SPL, OTCQX: SPHRY) is pleased to announce the appointment of Dr Jeff Davies as an independent non-executive director, effective 1 April 2022.  

Dr Davies is a former CSL executive, with over 35 years of biopharmaceutical experience, holding senior executive roles at CSL, including Executive Vice President & General Manager at CSL for the Asia-Pacific region, and Global Head of Plasma Product Research and Development at CSL-Behring, Switzerland.

Dr Davies was part of CSL’s due diligence teams which led to the acquisitions of Plasma Fractionation businesses of the Swiss Red Cross (2000) and Aventis Behring (2003) thus transforming CSL into a global company.

As Global Head of Plasma Product Research and Development at CSL-Behring, Dr Davies was responsible for CSL’s plasma product R&D strategy and programs conducted in Switzerland, Germany, Australia, USA and Japan. In this role he oversaw and played an important role in the development of leading products, including the multi-billion-dollar Privigen^® immunoglobulin product.

As Executive Vice President & General Manager at CSL for the Asia-Pacific region, Dr Davies had commercial and operational responsibility for the Asia-Pacific region. In this role, he oversaw the pharmaceutical, plasma, vaccine, and diagnostic businesses, employing over 1200 staff, in Australia (including the Broadmeadows and Parkville sites), China, and Asia-Pacific.

During his 30-year career at CSL, Dr Davies also held senior executive roles in R&D, regulatory affairs, clinical research, and medical affairs. Dr Davies is also a partner and founding director of the pharmaceutical consulting firm Centre for Biopharmaceutical Excellence.

Starpharma’s Chairman, Mr Rob Thomas said: “We are delighted to have Jeff join Starpharma as a non-executive director. He has deep operational expertise in the international pharmaceutical industry, with a track record of bringing highly successful products to market. Jeff’s extensive international R&D, regulatory, clinical, operations and commercial experience will be of great value to Starpharma through its next phase of growth.”

Dr Jeff Davies said: “I am very excited to join Starpharma’s board, having followed and admired the company for some years. Starpharma has an impressive commercial and development pipeline based on its proprietary dendrimer platform, with multiple high-value assets in the clinic and on market. I look forward to contributing to Starpharma’s future success.”

Dr Davies holds a PhD in Biochemistry from Monash University and is a Graduate of the Senior Executive Program from the London Business School.

Download full announcement here: Dr Jeff Davies appointed as non-executive director (PDF 298KB)